Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAND: Crizanlizumab in Sickle Cell Disease Patients With Vaso-Occlusive Crises
NCT03814746Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2019
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 21
01
Overview
A Phase 3 trial of crizanlizumab in sickle cell disease (SCD), sponsored by Novartis. Started Jul 2019; status: active, not recruiting.
02
Drugs
crizanlizumab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03814746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03814746.